Glycogen Storage Disease Type Ia , Gene & Cell therapies
BEAMBeam Therapeutics IncCatalyst overview
Research summary
This catalyst tracks a Phase 1/2 data readout for BEAM-301 in Glycogen Storage Disease Type Ia , Gene & Cell therapies. The expected timing is based on the latest available company guidance and may change.
8/6/24 - IND cleared. 5/6/25- First patient dosed. 8/5/25- Continue dosing in 2025. 11/4/25- Continue dosing of patients. 02/24/26:- Ph1/2 BEAM-301 GSDIa trial enrolling second cohort; initial clinical data expected in 2026. 05/07/26:- Open-label Ph1/2 dose-exploration BEAM-301 GSDIa trial ongoing; initial clinical data still expected in 2026. 08/04/26:- Initial Ph1/2 GSDIa clinical data still expected in 2026.
Verification
Confirm timing and program details against the company announcement or filing.